Larotrectinib discontinuation possible for some paediatric NTRK fusion-positive tumours
Children who respond to larotrectinib therapy for sarcoma with a neurotrophic tyrosine receptor kinase gene fusion may be able to discontinue treatment, indicates research published in the Journal of Clinical Oncology.
